Crizanlizumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized |
| Target | selectin P |
| Clinical data | |
| Trade names | Adakveo |
| Other names | SEG101, SelG1, crizanlizumab-tmca |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a620010 |
| License data | |
| Pregnancy category |
|
| Routes of administration | Intravenous |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6458H9948N1712O2050S58 |
| Molar mass | 146232.04 g·mol−1 |
Crizanlizumab, sold under the brand name Adakveo among others, is a monoclonal antibody medication that binds to P-selectin. It is a medication used to reduce the frequency of vaso-occlusive crisis in people aged 16 years and older who have sickle cell anemia. It is given by injection into a vein.
The most common side effects include joint pain, nausea, back pain, fever and abdominal (belly) pain.
Crizanlizumab was approved for medical use in the United States in November 2019. The EU's EMA withdrew authorization in May 2023 based on no significant effects from a phase 3 trial. The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication.